Migraine treatment shows promise for glaucoma prevention
Treatment with CGRP inhibitors, a class of drugs used to prevent migraine, appears to be associated with a reduced risk of glaucoma, researchers reported on May 6, 2026… read more.
Treatment with CGRP inhibitors, a class of drugs used to prevent migraine, appears to be associated with a reduced risk of glaucoma, researchers reported on May 6, 2026… read more.
People with self-reported poorer mental health also report worse quality of care and lower confidence in healthcare systems, according to a study published May 5th in the open-access journal PLOS… read more.
Although the United States requires a warning label on alcoholic beverages, alcohol-related deaths have risen steadily over the past two decades. However, new labels warning of specific disease… read more.
NICE(UK): Vorasidenib can be used as an option to treat grade 2 astrocytoma or oligodendroglioma in people 12 years and over when: i) the cancer has a susceptible… read more.
Insomnia is a common problem, affecting as many as 20% to 60% of perimenopausal and postmenopausal US women. Because of its possible severe physical and psychological effects, ongoing… read more.
Johnson & Johnson announced that the FDA has approved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of Caplyta (lumateperone) for… read more.
A new scoping review from the University of Toronto reveals that caregivers of loved ones with ovarian cancer face significant emotional strain, heavy caregiving responsibilities, and limited support… read more.
People with insurance through an employer or another commercial plan experienced an average wait time of 50 days for their first visit with a neurology provider, according to… read more.
The Nuffield Department of Women’s & Reproductive Health at the University of Oxford, together with Serac Healthcare Limited announces the publication of Phase 2 data in The Lancet Obstetrics and Gynaecology. The findings highlight the… read more.
A cancer diagnosis can upend any life. For young adults already navigating a step into independence, it can be especially distressing. But there are few evidence-based interventions to… read more.
H. Lundbeck A/S y presented new real-world 6-month results from the INFUSE study at the American Academy of Neurology (AAN) 2026 Annual Meeting, underscoring the importance of evaluating… read more.
The use of psilocybin, the hallucinogenic compound found in “magic mushrooms,” is rising in the United States alongside de‑criminalization efforts in several states and local jurisdictions, as well… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.